Results 51 to 60 of about 29,074 (242)

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade

Frontiers in Immunology
BackgroundThe introduction of checkpoint immunotherapeutic agents in the last decade has revolutionized cancer treatment. Although anti-PD-1, anti-PD-L1 and anti-CTLA4 are promising therapies, many patients fail to respond or relapse due to drug ...
Przemysław Bielski, Przemysław Bielski, Przemysław Bielski, Jan Barczyński, Jan Barczyński, Michał Mikitiuk, Michał Mikitiuk, Maja Myrcha, Kamil Rykała, Louis Boon, Wiktoria Gąsior, Aleksandra Hec-Gałązka, Tad A. Holak, Tomasz Sitar, Tomasz Sitar   +14 more
doaj   +1 more source

Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats

mAbs, 2020
The success of therapeutic antibodies is largely attributed for their exquisite specificity, homogeneity, and functionality. There is, however, a need to engineer antibodies to extend and enhance their potency.
Ami Miller, Stephen Carr, Terry Rabbitts, Hanif Ali   +3 more
doaj   +1 more source

Bispecific antibodies in cancer immunotherapy [PDF]

Human Vaccines & Immunotherapeutics, 2016
Cancer immunotherapy has recently generated much excitement after the continuing success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptor T cells, and other technologies are being actively studied.
Siqi, Chen, Jing, Li, Qing, Li, Zhong, Wang   +3 more
openaire   +2 more sources

Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion

Advanced Science, EarlyView.
The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li, Yuanxin Li, Asif Rashid, Hong Kee Tan, Shing Chan, Man Yan Hui, Wilson Yau Ki Chan, Kee See Lam, Yinping Liu, Wenwei Tu, Wing Leung   +10 more
wiley   +1 more source

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

OncoImmunology, 2021
Anti-programmed cell death-1 (PD-1)/PD-ligand-1 (PD-L1) treatments are effective in a fraction of patients with advanced malignancies. However, the majority of patients do not respond to it.
Haiping Jiang, Haiqing Ni, Pan Zhang, Xiaoli Guo, Min Wu, Haoran Shen, Jie Wang, Weiwei Wu, Zhihai Wu, Jiazheng Ding, Rong Tang, Shuaixiang Zhou, Bingliang Chen, Michael Yu, Hua Jing, Junjian Liu   +15 more
doaj   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs

Pharmaceutics
Background/Objectives: All current FDA-approved antibody–drug conjugates (ADCs) are single-target and single-payload molecules that have limited efficacy in patients due to drug resistance.
Nicole A. Wilski, Peter Haytko, Zhengxia Zha, Simin Wu, Ying Jin, Peng Chen, Chao Han, Mark L. Chiu   +7 more
doaj   +1 more source

Sensing and Reprogramming Surface Receptor Activation With Synthetic Transcriptional Circuits

Advanced Science, EarlyView.
A synthetic receptor‐signalling induced transcription (RESIT) circuit is designed based on receptor activation mediated split protease complementation and release of membrane‐tethered synthetic transcriptional modules. The RESIT system enables probing Ca2+ entry, receptor tyrosine kinase (RTK) activities and Ras activation, and reprogramming RTK ...
Fei Liu, Mei Yuan, Li‐Juan Tang, Fenglin Wang, Xia Chu, Jian‐Hui Jiang   +5 more
wiley   +1 more source

Antibodies to watch in 2026

mAbs
The Antibodies to Watch article series provides annual updates on commercial late-stage clinical development, regulatory review, and marketing approvals of antibody therapeutics.
Silvia Crescioli, Hélène Kaplon, Alicia Chenoweth, Yu-Shin Hsu, Kieran Pinto, Vaishali Kapoor, Janice M. Reichert   +6 more
doaj   +1 more source